Table 1 Study population characteristics.
Characteristics | N = 35 |
|---|---|
Age, years | |
Median (range) | 65 (41–82) |
≥70 years, n (%) | 11 (31.4) |
Gender, n (%) | |
Male | 22 (62.9) |
Female | 13 (37.1) |
ECOG PS, n (%) | |
0–1 | 27 (77.1) |
2 | 8 (22.9) |
Tumour location, n (%) | |
Right-sided | 4 (11.4) |
Left-sided | 17 (48.6) |
Rectum | 14 (40.0) |
Histological grade, n (%) | |
Low grade (G1–G2) | 22 (62.9) |
High grade (G3) | 2 (5.7) |
Unknown | 11 (31.4) |
RAS/BRAF mutational status, n (%) | |
RAS/BRAF wild type | 16 (45.7) |
RAS mutated | 17 (48.6) |
BRAF mutated | 2 (5.7) |
Mismatch repair protein expression, n (%) | |
Conserved | 35 (100) |
Tumour presentation, n (%) | |
Synchronous | 23 65.7) |
Metachronous | 12 (34.3) |
Primary tumour surgery, n (%) | 31 (88.6) |
Previous anti-VEGF therapy, n (%) | 33 (94.3) |
Bevacizumab, % | 57.1 |
Aflibercept, % | 8.6 |
Both, % | 28.6 |
Line of TAS-102 + bevacizumab treatment, n (%) | |
3 | 24 (68.6) |
4 | 4 (11.4) |
≥ 5 | 7 (20.0) |
Liver metastases, n (%) | 28 (80.0) |
No. of metastatic locations, n (%) | |
< 3 | 22 (62.9) |
≥ 3 | 13 (37.2) |
Time from metastatic disease diagnosis, n (%) | |
< 18 months | 10 (28.6) |
≥ 18 months | 25 (71.4) |
Tabernero prognostic classification, n (%) | |
Best | 3 (8.6) |
Good | 12 (34.3) |
Poor | 20 (57.1) |
